Huntsman CORPHUN

Huntsman Corporation filed a 425 with the SEC on July 29, 2026, the latest in a series of merger-related filings stretching back to July 14 that detail a proposed transaction with Olin Corporation. A Schedule 13G appeared the day before, on July 28, disclosing a passive holder crossing a reporting threshold. The 425 filings confirm that the S-4 registration statement has been announced and that the deal requires regulatory approvals plus sign-off from both Huntsman stockholders and Olin shareholders.

Huntsman is a global chemical manufacturer whose Performance Products division makes amines, maleic anhydride and carbonates for diverse industrial end markets. The company says its chemical products number in the thousands and are sold worldwide to manufacturers serving a broad range of industries. The licensing team works to ensure that Huntsman's patented technologies add value from planning through production. This is a real operating business with feedstock suppliers, logistics chains, manufacturing plants and customers, not a ticker searching for a thesis.

The latest available SEC financials paint an uncomfortable quarterly picture. Revenue from contracts with customers excluding assessed tax was $1.42 billion for the 10-Q period ending March 31, 2026. Net income attributable to the parent was a loss of $53.0 million, producing diluted EPS of negative $0.31 on 173.0 million weighted average diluted shares. Operating income was negative $16.0 million. Net cash used in operating activities was negative $53.0 million, and capex consumed another $38.0 million. Cash and equivalents stood at $369.0 million against total assets of $7.13 billion, liabilities of $4.23 billion and stockholders' equity of $2.68 billion.

The 425 filings from July 14 and July 15 outline the transaction mechanics and risk factors. The combined entity would pair Olin's capabilities with Huntsman's downstream products and formulation expertise, enabling what the filing calls OlinHuntsman. Risk factors listed include selling prices and supply-demand balance for both companies' products, excess industry capacity, reliance on a limited number of feedstock suppliers, third-party transportation dependence and the possibility of unexpected manufacturing disruptions.

Inventory built by $75.0 million during the quarter to a net balance of $885.0 million, a figure worth watching when operating cash flow is negative. R&D expense of $29.0 million suggests the product pipeline is still being funded. The full-year 10-K for the period ending December 31, 2025 shows revenues of $5.68 billion, giving a sense of annual scale against the weak first quarter.

What remains unproven from the supplied evidence is whether the Olin transaction will clear the required regulatory and shareholder approvals, what Olin's financials look like alongside Huntsman's, and whether the second quarter reverses the operating cash drain. The source rail does not include a chart route, analyst estimates, guidance figures or management commentary beyond what appears in the 425 risk factors. Deeper evidence would come from the next 10-Q, a joint proxy or an S-4 amendment with pro-forma combined financials.